This report contains market size and forecasts of Drug of Abuse (DOA) Testing in United States, including the following market information:
United States Drug of Abuse (DOA) Testing Market Revenue, 2016-2021, 2022-2027, ($ millions)
United States top five Drug of Abuse (DOA) Testing companies in 2020 (%)
The global Drug of Abuse (DOA) Testing market size is expected to growth from US$ XX million in 2020 to US$ XX million by 2027; it is expected to grow at a CAGR of XX% during 2021-2027.
The United States Drug of Abuse (DOA) Testing market was valued at US$ XX million in 2020 and is projected to reach US$ XX million by 2027, at a CAGR of XX% during the forecast period.
QYResearch has surveyed the Drug of Abuse (DOA) Testing Companies and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
United States Drug of Abuse (DOA) Testing Market,
United States Drug of Abuse (DOA) Testing Market Segment Percentages,
Urine
Saliva
Hair
Others
United States Drug of Abuse (DOA) Testing Market,
United States Drug of Abuse (DOA) Testing Market Segment Percentages,
Hospitals
Laboratories
Workplace
At-Home
Others
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Drug of Abuse (DOA) Testing revenues in United States market, 2016-2021 (Estimated), ($ millions)
Key companies Drug of Abuse (DOA) Testing revenues share in United States market, 2020 (%)
Further, the report presents profiles of competitors in the market, key players include:
Siemens
Merck
Roche
Thermo Fisher Scientific
Bio-Rad
Abbott
Quest Diagnostics
Psychemedics
United States Drug of Abuse (DOA) Testing Market Revenue, 2016-2021, 2022-2027, ($ millions)
United States top five Drug of Abuse (DOA) Testing companies in 2020 (%)
The global Drug of Abuse (DOA) Testing market size is expected to growth from US$ XX million in 2020 to US$ XX million by 2027; it is expected to grow at a CAGR of XX% during 2021-2027.
The United States Drug of Abuse (DOA) Testing market was valued at US$ XX million in 2020 and is projected to reach US$ XX million by 2027, at a CAGR of XX% during the forecast period.
QYResearch has surveyed the Drug of Abuse (DOA) Testing Companies and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
United States Drug of Abuse (DOA) Testing Market,
By Type
, 2016-2021, 2022-2027 ($ Millions)United States Drug of Abuse (DOA) Testing Market Segment Percentages,
By Type
, 2020 (%)Urine
Saliva
Hair
Others
United States Drug of Abuse (DOA) Testing Market,
By Application
, 2016-2021, 2022-2027 ($ Millions)United States Drug of Abuse (DOA) Testing Market Segment Percentages,
By Application
, 2020 (%)Hospitals
Laboratories
Workplace
At-Home
Others
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Drug of Abuse (DOA) Testing revenues in United States market, 2016-2021 (Estimated), ($ millions)
Key companies Drug of Abuse (DOA) Testing revenues share in United States market, 2020 (%)
Further, the report presents profiles of competitors in the market, key players include:
Siemens
Merck
Roche
Thermo Fisher Scientific
Bio-Rad
Abbott
Quest Diagnostics
Psychemedics
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.